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Abstract 
According to the CDC, about 79 million Americans are currently infected with Human 
papillomavirus (HPV) with an additional 14 million infected annually, most of which are 
teenagers and young adults. Of these 14 million newly diagnosed cases, approximately 27,000 
are diagnosed with a cancer caused by HPV. Kentucky’s HPV vaccination initiation and 
completion rates are below national estimates.  
In 2013, Kentucky’s vaccine completion rate for girls age 13 to 17 was 26.8 percent 
compared to United States completion rate of 37.6 percent. Kentucky vaccine completion rate for 
boys age 13 to 17 was 19 percent compared to a United States completion rate of 35 percent. 
It is estimated that for every 5 year delay of vaccinating against HPV will yield in 1.5 to 
2 million new cases of cervical cancer each year. There are three vaccines licensed by the FDA; 
Cervarix, Gardasil and Gardasil 9. These are all to be given in a 3-dose series with doses given at 
0, 1-2 and 6 months. It is imperative that primary care providers advocate for the recommended 
administration of the HPV vaccine and disseminate factual and up-to-date information to parents 
and caregivers.  
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Background and Significance 
HPV is a virus that is passed from direct skin contact, most commonly genital contact. 
HPV is incredibly prevalent in the community and many infected people show no identifiable 
symptoms, therefore the majority of people infected have no idea they have HPV. HPV can go 
away on its own, but can also cause serious health problems such as cervical, vaginal, vulvar, 
and anal cancer (U.S. Food and Drug Administration, 2014). 
There are several sexual lifestyle choices that individuals can make to lower their risk of 
getting HPV.  The earlier someone becomes sexually active and the more sexual partners the 
individual and their partner have, the higher their chances are of contracting HPV. The use of 
condoms does not impact an individual’s chances of getting HPV (U.S. Food and Drug 
Administration, 2014).  
Fortunately, there is a safe and effective option for protection against HPV.  The FDA 
and Advisory Committee on Immunization Practices (ACIP) have approved two vaccines for 
protection against HPV; Gardasil produced by Merck and Cervarix produced by 
GlaxoSmithKline (National Conference of State Legislatures, 2014).  Gardasil is a quadrivalent 
human papillomavirus vaccine that is recommended for both girls and boys. Cervarix is a 
bivalent human papillomavirus vaccine that is recommended for just girls. Both vaccines are 
recommended to be given at 11 to 12 years of age and in a 3-dose series. The second dose of the 
3-dose series should be administered 1 to 2 months after the first dose, and the third dose should 
be administered 6 months after the first dose (Center for Disease Control and Prevention, 2014). 
There are four strains of HPV that are responsible for 91 percent of cervical cancer cases 
(Centers for Disease Control and Prevention, 2014).  These four strains are 6, 11, 16, and 18. 
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Gardasil targets all four strains while Cervarix protects against strains 16 and 18 (National 
Conference of State Legislatures, 2014).  
Researchers believe that race and ethnicity play a significant epidemiological role in HPV 
related cervical cancer. Two times as many African American women than white women die 
from cervical cancer a year, statistically 5 vs 2.4 respectively per 100,000 (Moscicki, 2005). 
Hispanic women are also at increased risk for fatality in comparison to white women. There are 
3.4 Hispanic deaths per 1000,000 women annually (Moscicki, 2005). Cervical cancer is tightly 
linked with poor socioeconomic status and higher mortality rates in urban communities. Other 
substantially contributory risk factors include smoking, alcohol use, uncircumcised male partner, 
long term contraceptive use, multiple pregnancies, and HIV infection (Moscicki, 2005). 
Providers believe these statistical trends are a result of lack of access to routine Pape testing 
and/or poor compliance to initial or follow-up treatments (Centers for Disease Control and 
Prevention, 2014).  
It is evident that HPV is a silent threat to all women regardless their lifestyle choices and 
personal health compliance. Women of all walks of life are vulnerable and silent symptoms can 
quickly progress to a fatal virus that is currently taking thousands of women’s lives each year. 
However, there is a vaccine that if given per recommendation, can eliminate virtually 91 percent 
of cases (Centers for Disease Control and Prevention, 2014). 
Objectives 
The purpose of this study is to evaluate Kentucky Providers’ understanding and feelings 
towards the HPV Vaccine and the implementation in primary care practice. The goal is to 
identify demographic gaps and identify where intervention can yield the most impact.  
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A questionnaire titled “Evaluating Provider Knowledge of the HPV Vaccine in 
Kentucky” was sent to all members of the Kentucky Coalition of Nurse Practitioners & Nurse 
Midwives listserv. The purpose of this study is to evaluate Kentucky Providers’ understanding 
and feelings towards the HPV Vaccine and implementation in primary care practice. The goal is 
to isolate demographic gaps and identify where intervention can yield the most impact.  
Procedure 
Permission for this study was granted from the University of Kentucky Institutional 
Review Board, Exemption Certification for Protocol No. 16-0285-X1B. Permission was obtained 
via email from Lynne Cobb with Kentucky Coalition of Nurse Practitioners & Nurse Midwives 
(KCNPNM). KCNPNM listserv was used to disseminate the survey.  
Inclusion criteria for the study population included Nurse Practitioners practicing in the 
state of Kentucky and subscribed to the KCNPNM listserv. Exclusion criteria included those 
Nurse Practitioners in Kentucky that were not subscribed to the KCNPNM listserv. Age, race, 
discipline of practice, or any other demographics were utilized as exclusion criteria.  
Methods 
The instrument used to carry out this study was a questionnaire generated by REDCap. 
The questionnaire included 23 questions and took approximately 3 to 5 minutes to complete. 
Participants consented to taking the questionnaire and reserved the right to not answer any 
question they did not wish. The responses to the survey were anonymous which means no names 
appeared or were used on research documents, or used in presentations or publications. The 
survey was sent over KCNPNM listserv twice in a two-week period from April 11th to April 24th. 
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Results 
The survey had a total of 22 responders. Clinical significant findings included 8 of the 22 
responders reported working in a rural setting and all recommended the HPV vaccination to their 
patients’ parents or caregivers. Additionally, 6 of the 22 responders that reported they work 
exclusively with the pediatric populations also recommend the vaccine. Therefore, a 100% 
compliance rate was concluded from a rural and pediatric primary setting.  
Limitations 
The largest limitation was the number of responses and homogeneity of the responders, 
with 22 female participants. Although by design, the participants only represent Kentucky and 
therefore cannot be generalized nationally. All of the responders held a Masters or Doctorate 
degree in addition to 95% of responders were Caucasian and fully vaccinated. 
Conclusion 
A substantial gap between provider knowledge and actual implementation and 
administration of the HPV vaccine has been identified in Kentucky. There is an enormous 
opportunity at a pediatric, primary care and public health level to close this gap with provider 
advocacy and education. Moving forward, involvement in schools and at a legislative level is 
imperative to successful HPV vaccine implementation and administration and should be at the 
forefront of this movement.   
5/26/16, 9:01 AM
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Data Exports, Reports, and Stats
All data (all records and fields)
I am consenting to take this survey.
Total
Count
(N)
Missing Unique
22 0 (0.0%) 1
Counts/frequency: Yes (22, 100.0%), No (0, 0.0%)
What is your gender?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 1
University of Kentucky
Center for Clinical and Translational Research
Evaluation of Provider Knowledge of the HPV Vaccine in
Kentucky
0 6 12 18 24
Yes
No
 Download image
Appendix A.
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Counts/frequency: Male (0, 0.0%), Female (22, 100.0%)
What is your age?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 5
Counts/frequency: 21-30 (1, 4.5%), 31-40 (9, 40.9%), 41-50 (1, 4.5%), 51-60 (8, 36.4%), 60+ (3,
13.6%)
What is your ethnicity?
0 6 12 18 24
Male
Female
 Download image
0 3 6 9 12
21-30
31-40
41-50
51-60
60+
 Download image
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Total
Count
(N)
Missing Unique
22 0 (0.0%) 2
Counts/frequency: Caucasian (21, 95.5%), African American (0, 0.0%), Hispanic/Latino (0,
0.0%), American Indian/Alaska Native (0, 0.0%), Asian (0, 0.0%), Other (1, 4.5%)
How many children do you have, if any?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 3
Counts/frequency: I do not have children (5, 22.7%), 1 to 2 (10, 45.5%), 3 to 4 (7, 31.8%), 5+ (0,
0.0%)
0 6 12 18 24
Caucasian
African American
Hispanic/Latino
American Indian/...
Asian
Other
 Download image
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Do you have insurance?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 1
Counts/frequency: Yes (22, 100.0%), No (0, 0.0%)
Are you fully vaccinated?
Total
Count
(N)
Missing Unique
21 1 (4.5%) 1
Counts/frequency: Yes (21, 100.0%), No (0, 0.0%)
0 3 6 9 12
I do not have chi...
1 to 2
3 to 4
5+
 Download image
0 6 12 18 24
Yes
No
 Download image
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What is the highest degree you have achieved?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 2
Counts/frequency: BSN (0, 0.0%), MSN (12, 54.5%), DNP/PhD (10, 45.5%)
Are you a licensed Nurse Practitioner?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 1
Counts/frequency: Yes (22, 100.0%), No (0, 0.0%)
0 6 12 18 24
Yes
No
 Download image
0 3 6 9 12
BSN
MSN
DNP/PhD
 Download image
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What type of advanced practice provider licensure do
you hold?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 6
Counts/frequency: Family NP (11, 50.0%), Pediatric NP (6, 27.3%), Adult NP (1, 4.5%), Geriatric
NP (0, 0.0%), Women's Health NP (1, 4.5%), Neonatal NP (0, 0.0%), Acute Care NP (0, 0.0%),
Occupational Health NP (0, 0.0%), Certified Nurse Midwife (2, 9.1%), Family Psychiatric NP (1,
4.5%), Other (0, 0.0%)
0 6 12 18 24
Yes
No
 Download image
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What best describes your current work enviornment?
Total
Count
(N)
Missing Unique
0 3 6 9 12
Family NP
Pediatric NP
Adult NP
Geriatric NP
Women's Healt...
Neonatal NP
Acute Care NP
Occupational H...
Certified Nurse ...
Family Psychiat...
Other
 Download image
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22 0 (0.0%) 4
Counts/frequency: Primary Care/Office setting (14, 63.6%), Outpatient/Specialty Clinic (3,
13.6%), Acute/Critical care in a hospital (2, 9.1%), Academic setting (3, 13.6%)
How long have you been in clinical practice as a
provider?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 4
Counts/frequency: I do not work in a clinical setting (0, 0.0%), Less than 2 years (3, 13.6%), 2-4
years (3, 13.6%), 5-10 years (4, 18.2%), 10+ years (12, 54.5%)
0 4 8 12 16
Primary Care/Off...
Outpatient/Speci...
Acute/Critical car...
Academic setting
 Download image
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What is your work status?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 2
Counts/frequency: Full-time (16, 72.7%), Part-time (6, 27.3%), PRN/On-call (0, 0.0%)
0 3 6 9 12
I do not work in a...
Less than 2 years
2-4 years
5-10 years
10+ years
 Download image
0 5 10 15 20
Full-time
Part-time
PRN/On-call
 Download image
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Is your practice or place of employment considered more
rural or more urban?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 2
Counts/frequency: Rural (8, 36.4%), Urban (14, 63.6%), I do not know (0, 0.0%)
At what age do you feel, as a provider, it is appropriate to
initially discuss safe sex with the pediatric population?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 5
Counts/frequency: I do not work with pediatric patients and/or do not have an opinion (4,
18.2%), 9 to 10 year-old well-child check-up (7, 31.8%), 11 to 12 year-old well-child check-up (6,
27.3%), 13 to 14 year-old well-child check-up (4, 18.2%), 15 to 16 year-old well-child check-up
(1, 4.5%), I do not believe it is appropriate to initiate discussion until patient is sexually active (0,
0.0%)
0 4 8 12 16
Rural
Urban
I do not know
 Download image
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At what age do you actually discuss the HPV vaccine
with the pediatric population?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 3
Counts/frequency: I do not work with the pediatric population (6, 27.3%), 9 to 10 year-old well-
child check-up (5, 22.7%), 11 to 12 year-old well-child check-up (11, 50.0%), 13 to 14 year-old
well-child check-up (0, 0.0%), 15 to 16 year-old well-child check-up (0, 0.0%), I do not believe it
is appropriate to initiate discussion until patient is sexually active (0, 0.0%)
0 2 4 6 8
I do not work wit...
9 to 10 year-old ...
11 to 12 year-old ...
13 to 14 year-old...
15 to 16 year-old...
I do not believe it...
 Download image
5/26/16, 9:01 AMEvaluation of Provider Knowledge of the HPV Vaccine in Kentucky | REDCap
Page 12 of 21https://redcap.uky.edu/redcap/redcap_v6.13.2/DataExport/index.php?pid=5328&report_id=ALL&stats_charts=1
I recommend the HPV vaccine to my patients.
Total
Count
(N)
Missing Unique
22 0 (0.0%) 4
Counts/frequency: Yes (18, 81.8%), No (1, 4.5%), Sometimes (2, 9.1%), I do not see patients in
a clinical setting (1, 4.5%)
0 3 6 9 12
I do not work wit...
9 to 10 year-old ...
11 to 12 year-old ...
13 to 14 year-old...
15 to 16 year-old...
I do not believe it...
 Download image
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At what age do you actually offer the HPV vaccine?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 3
Counts/frequency: I do not work with the pediatric population (6, 27.3%), 9 to 10 year-old well-
child check-up (5, 22.7%), 11 to 12 year-old well-child check-up (11, 50.0%), 13 to 14 year-old
well-child check-up (0, 0.0%), 15 to 16 year-old well-child check-up (0, 0.0%), I do not believe it
is appropriate to initiate discussion until patient is sexually active (0, 0.0%)
0 5 10 15 20
Yes
No
Sometimes
I do not see pati...
 Download image
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If a patient and/or guardian decline the HPV vaccine, I
follow-up and offer additional and factual information at
the same appointment.
Total
Count
(N)
Missing Unique
22 0 (0.0%) 4
Counts/frequency: Never (2, 9.1%), Sometimes (5, 22.7%), Always (13, 59.1%), I do not see
patients in a clinical setting (2, 9.1%)
0 3 6 9 12
I do not work wit...
9 to 10 year-old ...
11 to 12 year-old ...
13 to 14 year-old...
15 to 16 year-old...
I do not believe it...
 Download image
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When searching for medical guidance, do you primarily
use a general search engine or seek professional
guidance from an accredited source? Choose all that
apply.
Total
Count
(N)
Missing Unique
22 0 (0.0%) 7
Counts/frequency: Google search (7, 31.8%), Google Scholar (6, 27.3%), American Academy of
Pediatrics (9, 40.9%), Center for Disease Control (17, 77.3%), American Academy of Nurse
Practitioners (8, 36.4%), NAPNAP (6, 27.3%), Social Media (0, 0.0%), I call my provider (0, 0.0%),
I do not use any of the above methods (3, 13.6%)
0 4 8 12 16
Never
Sometimes
Always
I do not see pati...
 Download image
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What social media platform do you use the most, if any?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 5
Counts/frequency: Facebook (12, 54.5%), Twitter (1, 4.5%), Instagram (2, 9.1%), LinkedIn (2,
9.1%), I do not use any of these forms of social media (0, 0.0%), I do not use social media (5,
22.7%)
0 5 10 15 20
Google search
Google Scholar
American Acade...
Center for Disea...
American Acade...
NAPNAP
Social Media
I call my provider
I do not use any ...
 Download image
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To your knowledge, is there a cure for HPV?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 2
Counts/frequency: Yes (0, 0.0%), No (21, 95.5%), I do not know (1, 4.5%)
0 3 6 9 12
Facebook
Twitter
Instagram
LinkedIn
I do not use any ...
I do not use soci...
 Download image
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I think the HPV vaccine is safe and effective.
Total
Count
(N)
Missing Unique
22 0 (0.0%) 2
Counts/frequency: Yes (21, 95.5%), No (1, 4.5%), I do not know (0, 0.0%)
Do you feel there are barriers to the HPV vaccine in the
primary care setting?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 4
0 6 12 18 24
Yes
No
I do not know
 Download image
0 6 12 18 24
Yes
No
I do not know
 Download image
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Counts/frequency: Yes (12, 54.5%), No (4, 18.2%), Sometimes (4, 18.2%), I do not know (2,
9.1%)
If you answered yes to the above questions, what
specific barriers do you find?
Total
Count
(N)
Missing
14 8 (36.4%)
It is a priority that the HPV vaccine is administered at 11
and 12 year-old well-child check-ups.
Total
Count
(N)
Missing Unique
22 0 (0.0%) 5
Counts/frequency: Strongly disagree (2, 9.1%), Disagree (1, 4.5%), Neutral/I do not care (1,
4.5%), Agree (9, 40.9%), Strongly Agree (9, 40.9%)
0 3 6 9 12
Yes
No
Sometimes
I do not know
 Download image
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Complete?
Total
Count
(N)
Missing Unique
22 0 (0.0%) 1
Counts/frequency: Incomplete (0, 0.0%), Unverified (0, 0.0%), Complete (22, 100.0%)
0 3 6 9 12
Strongly disagree
Disagree
Neutral/I do not c...
Agree
Strongly Agree
 Download image
0 6 12 18 24
Incomplete
Unverified
Complete
 Download image
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